Se Joon Woo, MD, PhD; Miroslav Veith, MD; Jan Hamouz, MD; et al.
This randomized clinical trial compares the efficacy, safety, and immunogenicity of SB11, a ranibizumab biosimilar product, with that of the reference ranibizumab for patients with neovascular age-related macular degeneration (AMD).